Abstract
Peptide drugs represent 5% of the global pharmaceutical market, but growing twice as fast as the rest of the drug market. The development of peptide therapeutics is challenging due to their low stability, short half-life, and poor oral bioavailability. However, peptides typically have exquisite potency, selectivity, and low toxicity, making them particularly attractive for certain disease targets. Significant technological innovations have enabled the rapid advancement of peptide therapeutics to the clinic. Here, strategies to improve peptide proteolytic stability and prolong half-life are discussed. Structural modifications are highly effective for enhancing peptide stability, including replacing the natural L-amino acids with D- or unnatural amino acids, peptide backbone modifications, protecting N- and C-termini, and cyclization. In vitro and in vivo assays are available to assess peptide stability and develop structure-stability relationships to enable the design of more stable peptides. Peptides will continue to play an important role in filling the gaps between small molecule drugs and protein therapeutics.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- ADA:
-
antidrug antibody
- BBMV:
-
brush border membrane vesicles
- CaV:
-
voltage-gated calcium channel
- CNS:
-
central nervous system
- CYP:
-
cytochrome P450
- DPP-4:
-
dipeptidyl peptidase 4
- EDTA:
-
ethylenediaminetetraacetic acid
- Fa:
-
fraction absorbed
- Fc:
-
fragment crystallizable
- GI:
-
gastrointestinal
- GIP:
-
glucose-dependent insulinotropic polypeptide
- GLP-1:
-
glucagon-like-peptide-1
- HIV:
-
human immunodeficiency virus
- HPLC:
-
High-performance liquid chromatography
- LC-MS:
-
liquid chromatography–mass spectrometry
- MW:
-
molecular weight
- PK/PD:
-
pharmacokinetics/pharmacodynamics
- PMSF:
-
phenylmethylsulfonyl fluoride
- SAR:
-
structure-activity relationship
- SC:
-
subcutaneously
- SGF:
-
simulated gastric fluid
- SIF:
-
simulated intestinal fluid
- T2DM:
-
type 2 diabetes mellitus
- TMDD:
-
target-mediated drug disposition
- UGT:
-
uridine 5′-diphospho-glucuronosyltransferase
References
Adessi C, Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr Med Chem. 2002;9:963–78.
Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195–202.
Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P-A, Sandqvist M, Bavenholm P, Efendic S, Eriksson JW, Dickinson S, Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002;25:869–75.
Anderson J. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. Future Oncol. 2009;5:433–43.
Aridoss G, Kim D-M, Kim JI, Kang JE. Ziconotide (ω-conotoxin MVIIA)-Efficient solid-phase synthesis of a linear precursor peptide and its strategic native folding. Pept Sci. 2021;113(5):e24223.
Barr RK, Verdile G, Wijaya LK, Morici M, Taddei K, Gupta VB, Pedrini S, Jin L, Nicolazzo JA, Knock E, Fraser PE, Martins RN. Validation and characterization of a novel peptide that binds monomeric and aggregated β-Amyloid and inhibits the formation of neurotoxic oligomers. J Biol Chem. 2016;291:547–59.
Ben-Yedidia T, Beignon A-S, Partidos CD, Muller S, Arnon R. A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization. Mol Immunol. 2002;39:323–31.
Bendre S, Zhang Z, Kuo H-T, Rousseau J, Zhang C, Merkens H, Roxin A, Benard F, Lin K-S. Evaluation of Met-Val-Lys as a renal brush border enzyme-cleavable linker to reduce kidney uptake of 68Ga-labeled DOTA-conjugated peptides and peptidomimetics. Molecules. 2020;25:3854.
Biber J, Stieger B, Stange G, Murer H. Isolation of renal proximal tubular brush-border membranes. Nat Protoc. 2007;2:1356–9.
Booka AI, Lechanteur A, Fillet M, Piel G. Therapeutic peptides for chemotherapy: trends and challenges for advanced delivery systems. Eur J Pharm Biopharm. 2021; Published ahead of print
Boschi-Muller S, Gand A, Branlant G. The methionine sulfoxide reductases: catalysis and substrate specificities. Arch Biochem Biophys. 2008;474:266–73.
Bottger R, Hoffmann R, Knappe D. Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. PLoS One. 2017;12:e0178943/1-e43/15.
Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-127-35 peptide: implications for peptide vaccines. Int J Cancer. 1999;83:326–34.
Buckley ST, Vegge A, Pyke C, Ahnfelt-Ronne J, Madsen KG, Scheele SG, Alanentalo T, Kirk RK, Pedersen BL, Skyggebjerg RB, Benie AJ, Strauss HM, Wahlund P-O, Bjerregaard S, Knudsen LB, Baekdal TA, Maarbjerg SJ, Sondergaard FL, Borregaard J, Hartoft-Nielsen M-L, Farkas E, Fekete C, Fekete C. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10
Chen X-W, He Z-X, Zhou Z-W, Yang T, Zhang X, Yang Y-X, Duan W, Zhou S-F. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42:999–1024.
Chen X, Mietlicki-Baase EG, Barrett TM, McGrath LE, Koch-Laskowski K, Ferrie JJ, Hayes MR, James Petersson E. Thioamide substitution selectively modulates proteolysis and receptor activity of therapeutic peptide hormones. J Am Chem Soc. 2017;139:16688–95.
Chen Y, Li T, Li J, Cheng S, Wang J, Verma C, Zhao Y, Chuanliu W. Stabilization of peptides against proteolysis through disulfide-bridged conjugation with synthetic aromatics. Org Biomol Chem. 2017;15:1921–9.
Chiu Y-Y, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res. 2003;20:749–56.
Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab. 2006;7:367–74.
Cossum PA. Role of the red blood cell in drug metabolism. Biopharm Drug Dispos. 1988;9:321–36.
Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des. 2013;81:136–47.
Darlak K, Benovitz DE, Spatola AF, Grzonka Z. Dermorphin analogs: resistance to in vitro enzymic degradation is not always increased by additional D-amino acid substitutions. Biochem Biophys Res Commun. 1988;156:125–30.
Dasgupta P, Singh A, Mukherjee R. N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells. Biol Pharm Bull. 2002;25:29–36.
Davenport AP, Scully CCG, de Graaf C, Brown AJH, Maguire JJ. Advances in therapeutic peptides targeting G protein-coupled receptors. Nat Rev Drug Discov. 2020;19:389–413.
Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 2015;17:134–43.
Di L, Kerns EH. Drug-like properties: concepts, structure design, and methods. Elevier: London; 2016.
Dishon S, Nussbaum G, Schumacher A, Fanous J, Hoffman A, Talhami A, Gilon C, Kassis I, Karussis D. Development of a novel backbone cyclic peptide inhibitor of the innate immune TLR/IL1R signaling protein MyD88. Sci Rep. 2018;8:9476.
Driggers EM, Hale SP, Lee J, Terrett NK. The exploration of macrocycles for drug discovery – an underexploited structural class. Nat Rev Drug Discov. 2008;7:608–24.
Duckworth WC, Gennett RG, Hamel FG. Insulin degradation: progress and potential. Endocr Rev. 1998;19:608–24.
Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002;25:1398–404.
Elfgen A, Bochinsky K, Tusche M, Gering I, Hartmann R, Kutzsche J, Willbold D, Hupert M, de Gonzalez SRME, Huesgen PF, Santiago-Schubel B, Kutzsche J, Sacchi S, Pollegioni L, Sacchi S, Pollegioni L, Willbold D. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers. Sci Rep. 2019;9:5715.
Esposito S, Deventer K, Geldof L, Van Eenoo P. In vitro models for metabolic studies of small peptide hormones in sport drug testing. J Pept Sci. 2015;21:1–9.
Evans BJ, King AT, Katsifis A, Matesic L, Jamie JF. Methods to enhance the metabolic stability of peptide-based PET radiopharmaceuticals. Molecules. 2020;25:2314.
Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100:49–58.
Gentilucci L, De Marco R, Cerisoli L. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr Pharm Des. 2010;16:3185–203.
Goldberg M, Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nat Rev Drug Discov. 2003;2:289–95.
Goodwin D, Simerska P, Toth I. Peptides as therapeutics with enhanced bioactivity. Curr Med Chem. 2012;19:4451–61.
Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O’Harte FPM, Flatt PR. N-terminal His7-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol. 2004;180:379–88.
Harris AG. Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. Gut. 1994;35:S1–4.
Ho M-CD, Ring N, Amaral K, Doshi U, Albert PL. Human enterocytes as an in vitro model for the evaluation of intestinal drug metabolism: characterization of drug-metabolizing enzyme activities of cryopreserved human enterocytes from twenty-four donors. Drug Metab. Dispos. 2017;45:686–91.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf
Irwin N, Green BD, Gault VA, Greer B, Harriott P, Bailey CJ, Flatt PR, O’Harte FPM. Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. J Med Chem. 2005;48:1244–50.
Jing X, Jin K. A gold mine for drug discovery: strategies to develop cyclic peptides into therapies. Med Res Rev. 2020;40:753–810.
John H, Maronde E, Forssmann W-G, Meyer M, Adermann K. N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP-and insulin releasing capacity. Eur J Med Res. 2008;13:73–8.
Jyrkas J, Tolonen A. Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds. J Pharm Biomed Anal. 2021;196:113921.
Kapitza C, Nosek L, Jensen L, Hartvig H, Jensen CB, Flint A. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. J Clin Pharmacol. 2015;55:497–504.
Keefer C, Chang G, Carlo A, Novak JJ, Banker M, Carey J, Cianfrogna J, Eng H, Jagla C, Johnson N, Jones R, Jordan S, Lazzaro S, JianHua Liu R, Obach S, Riccardi K, Tess D, Umland J, Racich J, Varma M, Visswanathan R, Di L. Mechanistic insights on clearance and inhibition discordance between liver microsomes and hepatocytes when clearance in liver microsomes is higher than in hepatocytes. Eur J Pharm Sci. 2020;155:105541.
Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.
Kyriakakis N, Chau V, Lynch J, Orme SM, Murray RD. Lanreotide autogel in acromegaly – a decade on. Expert Opin. Pharmacother. 2014;15:2681–92.
Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T. Discovery of the once-weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58:7370–80.
Lee AC-L, Harris JL, Khanna KK, Hong J-H. A comprehensive review on current advances in peptide drug development and design. Int J Mol Sci. 2019;20:2383/1-83/21.
Li H, Kem DC, Zhang L, Huang B, Liles C, Benbrook A, Gali H, Veitla V, Scherlag BJ, Cunningham MW, Xichun Y. Novel retro-inverso peptide inhibitor reverses angiotensin receptor autoantibody-induced hypertension in the rabbit. Hypertension. 2015;65:793–9.
Li X, Wang S, Zhu X, Zhangsun D, Yong W, Luo S. Effects of cyclization on activity and stability of α-conotoxin TxIB. Mar Drugs. 2020;18:180.
Liao S, Liang Y, Zhang Z, Li J, Wang J, Wang X, Dou G, Zhang Z, Liu K. In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products. PLoS One. 2015;10:e0116805/1–e05/18.
Maher S, Mrsny RJ, Brayden DJ. Intestinal permeation enhancers for oral peptide delivery. Adv Drug Deliv Rev. 2016;106:277–319.
Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Med Drug Discovery. 2021;9:100075.
Marastoni M, Salvadori S, Scaranari V, Spisani S, Reali E, Traniello S, Tomatis A. Synthesis and activity of new linear and cyclic peptide T derivatives. Arzneim-Forsch. 1994;44:1073–6.
Mathur D, Singh S, Mehta A, Agrawal P, Raghava GPS. In silico approaches for predicting the half-life of natural and modified peptides in blood. PLoS One. 2018;13:e0196829/1-e29/10.
Mocsai A, Kovacs L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014;12:43/1-43/9, 9.
Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20:309–25.
Nielsen DS, Shepherd NE, Xu W, Lucke AJ, Stoermer MJ, Fairlie DP. Orally absorbed cyclic peptides. Chem Rev. 2017;117:8094–128.
Pollaro L, Heinis C. Strategies to prolong the plasma residence time of peptide drugs. Med Chem Commun. 2010;1:319–24.
Rafferty B, Coy DH, Poole S. Pharmacokinetic evaluation of superactive analogs of growth hormone-releasing factor (1-29)-amide. Peptides (Fayetteville, N Y). 1988;9:207–9.
Ramon J, Saez V, Baez R, Aldana R, Hardy E. PEGylated interferon-α2b: a branched 40K polyethylene glycol derivative. Pharm Res. 2005;22:1374–86.
Salhanick AI, Clairmont KB, Buckholz TM, Pellegrino CM, Ha S, Lumb KJ. Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide. Bioorg Med Chem Lett. 2005;15:4114–7.
Schaffner P, Dard MM. Structure and function of RGD peptides involved in bone biology. Cell Mol Life Sci. 2003;60:119–32.
Schiller PW, Weltrowska G, Berezowska I, Nguyen TMD, Wilkes BC, Lemieux C, Chung NN. The TIPP opioid peptide family: development of δ antagonists, δ agonists, and mixed μ agonist/δ antagonists. Biopolymers. 2000;51:411–25.
Sharma A, Singla D, Rashid M, Raghava GPS. Designing of peptides with desired half-life in intestine-like environment. BMC Bioinf. 2014;15:282/1–8.
Sharma R, McDonald TS, Eng H, Limberakis C, Stevens BD, Patel S, Kalgutkar AS. In vitro metabolism of the glucagon-like peptide-1 (GLP-1)-derived metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in mouse and human hepatocytes. Drug Metab Dispos. 2013;41:2148–57.
Steinberg M. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther. 2009;31:2312–31.
Stroemstedt AA, Pasupuleti M, Schmidtchen A, Malmsten M. Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. Antimicrob Agents Chemother. 2009;53:593–602.
Sylvestre M, Lv S, Yang LF, Luera N, Peeler DJ, Chen B-M, Roffler SR, Pun SH. Replacement of L-amino acid peptides with D-amino acid peptides mitigates anti-PEG antibody generation against polymer-peptide conjugates in mice. J Control Release. 2021;331:142–53.
Tugyi R, Mezo G, Fellinger E, Andreu D, Hudecz F. The effect of cyclization on the enzymatic degradation of herpes simplex virus glycoprotein D derived epitope peptide. J Pept Sci. 2005;11:642–9.
Veine DM, Yao H, Stafford DR, Fay KS, Livant DL. A d-amino acid containing peptide as a potent, noncovalent inhibitor of α5β1 integrin in human prostate cancer invasion and lung colonization. Clin Exp Metastasis. 2014;31:379–93.
von Hentig N. Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today. 2008;44:103–32.
Wakankar AA, Borchardt RT. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci. 2006;95:2321–36.
Werle M, Bernkop-Schnuerch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids. 2006;30:351–67.
Wu C-Y, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther (St Louis). 1995;58:492–7.
Wu H, Huang J. Optimization of protein and peptide drugs based on the mechanisms of kidney clearance. Protein Pept Lett. 2018;25:514–21.
Yang JZ, Chen W, Borchardt RT. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs. J Pharmacol Exp Ther. 2002;303:840–8.
Yao J-F, Yang H, Zhao Y-Z, Xue M. Metabolism of peptide drugs and strategies to improve their metabolic stability. Curr Drug Metab. 2018;19:892–901.
Zaman R, Islam RA, Ibnat N, Othman I, Zaini A, Lee CY, Chowdhury EH. Current strategies in extending half-lives of therapeutic proteins. J Control Release. 2019;301:176–89.
Zvereva I, Dudko G, Dikunets M. ’Determination of GnRH and its synthetic analogues’ abuse in doping control: small bioactive peptide UPLC-MS/MS method extension by addition of in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameter fluctuations as suitable biomarkers. Drug Test Anal. 2018;10:711–22.
Zvereva I, Semenistaya E, Krotov G, Rodchenkov G. Comparison of various in vitro model systems of the metabolism of synthetic doping peptides: proteolytic enzymes, human blood serum, liver and kidney microsomes and liver S9 fraction. J Proteome. 2016;149:85–97.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Shi, S.M., Di, L. (2022). Strategies to Optimize Peptide Stability and Prolong Half-Life. In: Jois, S.D. (eds) Peptide Therapeutics. AAPS Advances in the Pharmaceutical Sciences Series, vol 47. Springer, Cham. https://doi.org/10.1007/978-3-031-04544-8_4
Download citation
DOI: https://doi.org/10.1007/978-3-031-04544-8_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-04543-1
Online ISBN: 978-3-031-04544-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)